cephalon

Pharmaceuticals are facing big patent cliff problems this year, but several biotechnology stocks have been doing quite well: Their biologic drugs command high prices, tend become blockbusters, and they are in far less danger from generic competition. Here are the big winners so far this year.

The Feds -- and consumers -- may finally have had it with 'pay-for-delay.' In these deals, generic drug companies that challenge a patent held by a name-brand pharmaceuticals agree to settle by delaying their entry into the market in return for a payment. But regulators are now calling for laws to end the practice.

Jet lag is a drag. There's no better way to put it. Melatonin, warm baths, herbal teas and meditation are all supposed "cures," but no really agrees on whether they really work. A transatlantic or transpacific flight can turn even the fittest among us into zombies for days. Now comes news from...